Plus, Company Spotlights its Successful First-in-human Clinical Study Results at Premier Eye Care and Investor Conferences
SAN DIEGO, CA, USA (Business Wire, June 8th, 2021) –
Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces its new corporate branding and new website. The new corporate logo was designed to better reflect and illustrate the purpose and passion underlying the Company’s goal to use the MediPrint process to help protect sight by printing ophthalmic drugs on the surface of contact lenses. Additionally, the new web site is www.mediprintlens.com.
The Company’s new web site showcases the innovative pharmaceutical vision and sight-protecting mission of the enterprise and its team. It contains information on how MediPrint Ophthalmics is initially developing a highly innovative solution for a significant unmet need in glaucoma. Also, the Company’s pipeline of products, including those for dry eye and allergy, which are all based on its proprietary MediPrint™ process and contact lenses, is highlighted.
Dan Myers, the company’s CEO, was selected to present the successful Phase 2a data from the Company’s first in-human clinical study SIGHT-1 (Sustained Innovative Glaucoma and ocular Hypertension Treatment) with LLT-BMT1, a drug-eluting contact lens to treat mild to moderate glaucoma and ocular hypertension. Dan presented at ARVO 2021 and at the LSI 2021 Emerging Medtech Summit. Additionally, he attended SECO to discuss the data and the Company’s direction with leading eye care professionals.
“I am highly encouraged by the reception we’ve received from eye care professionals and from investors as we share our story at leading conferences and, now more openly, on the internet,” said Dan Myers, CEO of MediPrint Ophthalmics. “SIGHT-1’s positive tolerability and safety results give us great confidence to proceed swiftly with our next clinical study, SIGHT-2, in which we will optimize dosing to take to our Phase 3 trials. And, the exposure our new corporate branding and new web site provides us for sharing our story is key as we aim to raise a Series A round of financing to propel the advancement of our key assets.”
About MediPrint Ophthalmics
MediPrint™ Ophthalmics (formerly Leo Lens Pharma) is an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight by developing and commercializing a proprietary ocular drug delivery portfolio. The Company is currently advancing its lead asset, a unique and complete glaucoma treatment, to the clinic while continuing to build out its product portfolio for dry eye and for allergy, and subsequently for other anterior and posterior segment conditions. Using its proprietary MediPrint process, MediPrint Ophthalmics will initially commercialize a drug-eluting, comfort-enhancing, preservative-free contact lens to treat millions of glaucoma patients worldwide. While eye drops have been around for over 40 years and remain the standard of care for over 90% of patients, they have only around a 50% compliance rate. This leads millions to suffer from disease progression and thousands to suffer from preventable blindness. There is a large unmet need for a better non-invasive treatment option in this $4B U.S. market. MediPrint Ophthalmics’ patented MediPrint process offers a unique value proposition for patients, practitioners, strategic partners, and payers.
For more information, please visit www.mediprintlens.com.
Company Contact: Kenny Key
MediPrint Ophthalmics, Inc. 858-522-0815 kkey@mediprintlens.com
Media Contact:
Orlando Rodrigues
COR Communications 760-212-5727 orlando@mediprintlens.com